This article discusses the potential role of the cytokine cycle and its corollary as drivers of the relentless progression of Alzheimer's neuropathologies, whether they are the result of gene mutations, gene polymorphisms, and/or environmental and comorbid conditions. Based on the discovery of cytokine overexpression as an accompaniment to the dementia-related glial activation, the cytokine hypothesis was
changes are cumulative. Similarly, progression of plaques from a non-neuritic, diffuse appearance to one of compact deposits is suggested by the appearance of different Aβ plaque types. These include diffuse Aβ deposits, diffuse neuritic Aβ plaques, dense-core neuritic Aβ plaques, and dense core non-neuritic Aβ plaques within a single tissue section.
Neurofibrillary progression is suggested by the formation of 'threads' of paired helical filaments scattered within neuronal cytoplasm, along with other cells in which fully-formed tau tangles push aside the nucleus and acellular tangles that appear to have remained after the death and dissolution of a neuron.
Such progression suggests the presence of driver(s) of these events, which, even without repetition of the causative event(s) or agent(s), result in self-propagation of the neurodegenerative events that culminate in increasing densities of these neuropathological changes.
This article discusses the common themes in neuropathogenesis:
• potential causative factors (gene mutations and gene duplication);
• risk-conferring factors (gene polymorphisms, environmental and comorbid conditions and aging); and
• omnipresent glial activation and excessive expression of putative drivers (these have been found to be factors that promote furtherance of neurodegenerative events).
Causative Factors
Gene Mutations-APP and PSEN1 and PSEN2 This discovery was quickly followed by others demonstrating the structure and size of the Aβ peptide necessary for fibril formation 3,4 and mapping of the amyloid precursor protein (APP) gene for the β-amyloid precursor protein (βAPP) to chromosome (Chr) 21.
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The known occurrence of families with autosomal-dominantly inherited AD led to studies linking mutations in the βAPP coding region to familial AD (FAD). 5,9,10 Although additional family-linked APP gene mutations were identified in subsequent searches, they did not account for all the known familial cases. Studies of such families revealed specific mutations in two other gene sequences that are causative for AD: presenilins (PSEN) 1 and 2. These genes are located on Chr 1 (PSEN2) and Chr 14 (PSEN1). [11] [12] [13] [14] Inheritance of any one of these autosomal-dominant, highly penetrant missense mutations in the APP or PSEN genes causes the development of early-onset AD. More recently, early-onset cases have been attributed to promoter mutations that merely elevate the expression of βAPP.
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Taken together, mutations in the APP, PSEN1, and PSEN2 genes account for the vast majority of familial cases. 16 Of the three genes, the 173 recognized mutations in PSEN1 are responsible for most cases. These circumstances suggest that the expected increase due to gene loading is augmented by factors that act to elevate βAPP protein levels, perhaps including activated glia and the cytokines they overexpress in the mature brain. 56, 57 This idea, together with previous studies suggesting a role for glia in plaque formation, 58,59 is supported by a series of investigations demonstrating the potential of these cytokines to act as generators and promoters of the neuropathological sequelae of AD, i.e.:
• Aβ plaques; [60] [61] [62] • neurofibrillary tangles; [63] [64] [65] [66] • dysregulation of neurotransmitters;
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• growth factor levels; 68 and
• DNA damage and neuron loss.
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Neurodegenerative Disease Alzheimer's Disease • the extra copy of Chr 21 in DS is present in the zygote so that all the players, including the 1.5-fold gene loading and its downstream consequences, are in place at conception; and
• the innate and, to date unstoppable, outcome is AD.
Microglia and astrocytes had previously been found expressing excessive amounts of the systemic immune response-generating cytokine interleukin-1 (IL-1) and astrocyte-derived neuritogenic cytokine S100B, respectively, in the AD brain. Considering the relationships between DS and AD, Griffin et al. set out to assess elements of an innate immune response in the DS brain. They wanted to explore the possibility that changes that are nearly universal in the DS brain would render it a suitable system for studying drivers of AD pathogenesis.
Compared with the brains of non-DS individuals of similar ages, IL-1 and S100B were highly overexpressed in activated glia, even in the brains of fetuses, neonates, and children with DS. 56 This age distribution is important; neither Aβ plaques nor neurofibrillary tangles were noted in these brains, nor have these AD neuropathological anomalies been reported in brains from DS individuals of these ages. 84, 85 Thus, several studies underscore the importance of these cytokines and precocious development of Aβ plaques and neurofibrillary tangles in DS.
These show:
• the increase in IL-1 and S100B expression in DS prior to the detection of either Aβ plaques or neurofibrillary tangles; 56, 57 • the capacity of both IL-1 86 and S100B to elevate neuronal βAPP;
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• the induction of tau phosphorylation through IL-1-induced activation of mitogen-activated protine kinase p-38; 65 and
• the relation of overexpression of IL-1 and S100B to both Aβ 93 This may be related to the expanding evidence for an inhibition of neurogenesis by IL-1.
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Animal Models
The creation of mouse models of FAD through transgenesis with mutations or deletions of APP, PSEN1, and PSEN2 have greatly aided in the understanding of AD pathogenesis.
Glial activation is a prominent feature in these models from the first FAD-mutant APP (V717F) transgenic mouse model. 20 In more recent studies, astrocyte activation in V717F transgenic mice was shown to be accompanied by microglial activation months before the appearance of Aβ plaques in these animals.
Compared with littermate-controls (non-transgenic mice), V717F mice had elevated numbers of activated astrocytes overexpressing S100B as early as two months of age, while the first Aβ plaques were not found until eight months. 96 The tissue levels of S100B mRNA and protein were elevated at each month from the second to eighth and from that time were correlated with Aβ load in these mice. 96 In addition, the expression of the IL-1β-converting enzyme is greatly increased in these mice, again before plaque formation, and was closely correlated with neuronal DNA damage and cell loss. This is consistent with the idea that increases in active IL-1β contribute to Aβ plaque formation and to neuronal degeneration in mouse models of AD and by analogy to AD. 70 Accompanying this astrocyte activation in V717F transgenic mice, there is microglial activation with overexpression of IL-1 and other inflammation parameters, again prior to Aβ plaque deposition. 97 Crossing another APP-transgenic mouse (Tg2576) with transgenic mice overexpressing S100B (TghuS100B) exaggerated the glial activation and increased expression of S100B above the level in the TghuS100B mice. It also increased expression of IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α) above the expression level in Tg2576 mice.
increase in glial activation and overexpression of these cytokines was an early phenomenon that foreshadowed an increase in plaque density and Aβ levels.
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A study of a mouse model in which PS-1 and PS-2 functions were eliminated (PSEN1 null mutation with conditional knockout of PSEN2) found: 98 • substantial glial activation;
• neuronal loss in the cortex and hippocampus;
• cortical and hippocampal atrophy; and
• tau hyperphosphorylation with tangle-like intraneuronal inclusions.
All of this occurred with no additional production of Aβ. The activation of glia and the accompanying increase in cytokines, such as S100B
and IL-1, may contribute to this neuronal dysfunction and loss, as demonstrated by Mori et al. 34 and Sheng et al.
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Growing evidence has suggested beneficial roles for microglial activation in transgenic mouse models of Aβ deposition. For instance, plaque burdens are increased by deficiencies in the chemokine receptor CCR2 99 or in the complement system. 99 Indeed, Aβ deposition occurs efficiently in the near absence of microglia. 100 Nevertheless, considerable evidence indicates that activated microglia and their products are detrimental in many experimental models and natural disease states. It is likely that microglia could contribute to Aβ removal while simultaneously producing agents that are detrimental to neurological structure/function and conducive to progression of pathology. As evidence, genetic ablation of the microglial fractalkine receptor CX 3 CR1 prevents neuronal loss in an APP-transgenic line: 20305648.
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Gene Polymorphisms as Risk Factors for Development of Alzheimer's Disease
Genetic anomalies, such as the gene mutations and duplication discussed above, account for very few of the many sporadic AD cases.
Inheritance of variants in specific sequences, i.e. polymorphisms, of a relatively small number of genes may contribute to these sporadic cases. Several such polymorphisms have been implicated in modifying the risk for development of AD.
In this article, the discussion includes the most important polymorphism, the ε4 variant of the apolipoprotein E (APOE) gene, which is moderately penetrant and confers high risk for development of AD. For the purpose of establishing a link between neuroinflammatory glial activation and excessive expression of proinflammatory cytokines, the genetic links to just two of these cytokines, TNFα and IL-1, are reviewed here. This exclusivity leaves further discussion of other important factors involved in AD pathogenesis to another review. These include components of the complement system and many other factors [101] [102] [103] that doubtless contribute to such pathogenesis and are deserving of a more sharply focused discussion.
Apolipoprotein E Gene
The gene polymorphism that is most important in AD risk is a single nucleotide substitution in the coding region of the APOE for apolipoprotein E (ApoE) on Chr 19, creating what is termed the ε4 allele. The resulting gene product-ApoE4-has an arginine-cysteine substitution at position 112 of its amino acid sequence. This alters the interaction of the protein with its receptor and increases AD risk. 104, 105 Individuals with two copies of the ε4 allele of APOE have a 50-90% chance of developing AD by the age of 85 and those with one copy have about a 45% chance.
The mechanisms underlying the genetic influence of APOE ε4 on AD risk are unknown, but hypotheses include an interaction with Aβ as plaques develop. 106 Inheritance of APOE ε4 is associated with increased Aβ plaque density 107 as well as neuronal pathologies. 108 In addition to this, ApoE is important for the molecular trafficking 109 and induction of neuronal expression of βAPP, perhaps in particluar with regard to specific genotypes of APOE. This is because the APOE ε3 variant is more effective at βAPP induction than APOE ε4.
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A good deal of evidence indicates an impact of APOE genotype on inflammatory sequelae. APOE ε4 was found to produce a dose-dependent increase in microglial activation and this effect was independent of Aβ deposition. 111 The protective effect of NSAID use is much stronger in APOE ε4 carriers; [112] [113] [114] [115] [116] Reports from the first phase of the multicenter AD Neuroimaging
Initiative (ADNI) are making major contributions to knowledge concerning correlations between neuroimaging and CSF analytes and AD progression. They are also helping discern the role of environmental, comorbid conditions and specific gene polymorphisms in increased risk or perhaps precocious development of AD neuropathological changes.
For instance in a new report from ADNI, genotypes, including APOE and two other 'promising genes' contactin 5 (CNTN5) and bridging integrator 1 (BIN1), were associated with a number of neuroimaging parameters. 124 More specifically, the inheritance of APOE ε4 and a maternal history of the disease were linked to hippocampal atrophy. 125 With regard to comorbid conditions, obesity is linked to lower brain volumes in AD and in mild cognitive impairment (MCI), a condition likely to be prodromal AD. 126 Importantly, there were indications of increased plaque burden by 3D imaging with the 'Pittsburgh compound' PiB correlate with hippocampal atrophy 127 as well as with progression from MCI to AD. 128 Similar correlations hold with CSF measurements of Aβ and tau. Worldwide ADNI efforts will aid in establishing the progression from early stages, i.e. MCI to AD. Such efforts will then be useful in defining the mechanisms involved in driving AD neuropathology as well as developing and analyzing rational strategies for therapeutic interventions. 129 
Tumor Necrosis Factor Alpha
In a study to identify polymorphisms in TNF, the gene encoding the proinflammatory cytokine TNFα, a polymorphism at -850 C/T in TNF was found to increase the risk for AD. 130 Specific polymorphisms in promoter regions of inflammatory cytokine genes, such as TNFα and IL-6, are associated with late-onset sporadic AD. 131 For instance, heterozygosity for a polymorphism at -1082 of the IL-10 gene increased the odds ratio of AD two-fold. When combined with a polymorphism at -308 in TNF, the odds ratio was increased 6.5 times.
Interleukin-1
Both IL1A and IL1B, which encode proteins IL-1α and IL-1β, map to two-to four-fold. [132] [133] [134] [135] [136] [137] Importantly, in another of study of living AD patients, a -889 polymorphism in IL1A was associated not only with increased an risk for AD (4.5 times) but also with earlier disease onset (seven to nine years earlier). 134 Although the numbers of studies supporting such an association is increasing, a few studies have failed to substantiate this. 138, 139 In one study, IL1B at -511 increased the odds for AD but the IL1A -889 polymorphism did not. 140 A strong association was shown between AD and IL1B +3954, but not -511 in another study. 141 Other studies have found no relation between IL1B-511 and AD. 142, 143 Meta-analyses have supported an association for at least the -889 polymorphism in the IL1A gene. [144] [145] [146] In the large Honolulu-Asia Aging Study, the authors concluded that certain loci within the IL-1 gene cluster were associated with AD. Inheritance of the polymorphisms in both IL1A and IL1B is associated with a much greater risk (~10 times) of developing AD. Until recently, little could be discerned regarding the relevance of age-related accumulations of Aβ plaques and neurofibrillary tangles, especially as to whether they were portents of later development of AD.
One study used in vivo Aβ labeling together with functional magnetic resonance imaging to test cognitively intact elderly individuals. Sperling and her colleagues found a relationship between Aβ deposit density and changes in a specific memory mode previously noted in AD patients. 154 These findings suggest that events during supposedly normal aging may presage memory loss and neural dysfunctions related to learning and memory. In this way, they may contribute to later development of AD, with greater memory dysfunction and neuropathological change. The changes highlight the importance of defining seminal events and triggers of the progressive acquisition of such Aβ deposits. This will help toward the development of rational strategies to halt or impede such acquisition. In this way it may be possible to prevent or delay consequent neural dysfunction and dementia.
Some cognitively intact individuals have large numbers of non-neuritic
Aβ deposits, but interestingly these deposits are not associated with activated microglia. This suggests that microglial activation contributes to the progression of Aβ deposits into the more mature neuritic Aβ plaques diagnostic of AD. 155 Even in individuals who are cognitively normal and who have few Aβ deposits or plaques, the density and activation state of astrocytes and microglia increase with advancing age. The levels of S100B expressoin gradually increase, 57,156 while the levels of IL-1 remain stable until the sixth decade. 157 The latter finding suggests that in normal aging, IL-1 levels are maintained at lower levels in order to delay neurodegenerative consequences.
Environmental Events that Contribute to Precocious (Age-inappropriate) Development of Alzheimer's Disease Neuropathological Changes
In addition to genetic mutation, gene duplication, gene polymorphisms, Indeed, this is the case when either epilepsy or head injury is assessed with regard to the influence of inheritance of an APOE ε4 allele; such inheritance adds to the risk for a poor outcome in both epilepsy and head injury. 158, 159 Conditions associated with an increased risk for AD are as wide ranging as:
• heart disease; 160 • AIDS; 161, 162 • obesity and diabetes; 126,163-168 and
• hypertension and heart disease. 165, [168] [169] [170] As with head injury and epilepsy, the risks conferred are increased in carriers of one or more APOE ε4 alleles. 164, 170, 171 In addition, head injury, epilepsy, and AIDS include early overexpression of βAPP and increases in neuroinflammatory cytokines, such as IL-1 and S100B. 82, [172] [173] [174] [175] [176] [177] In several of the conditions mentioned above, glial activation has been associated with neuropathological changes similar to those in AD; glial activation is sometimes present long before frank neurodegeneration is noted.
Conditions involving glial activation include:
• DS;
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• head injury; 172, 175 • epilepsy; 176, 177 • obesity and diabetes; 126,166,167 and
• AIDS. 
